Back

Cardiovascular effects of BRAF and MEK inhibitors in patients with melanoma: a prospective study incorporating risk scores, cardiac biomarkers and cardiovascular magnetic resonance imaging

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiovascular complications in cardio-oncology: risk assessment Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Claire Glen

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
The prognostic significance of Weber and ventilatory CPET classifications in amyloidosis patients
Doctor L. Ortega Aviles (Rochester, US) Doctor S. Santos Patarroyo (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Assessment of poor cardiovascular health metrics and related disparities among cancer patients in the United States: a nationwide analysis of over 1.5 million individuals
Doctor S. Abohashem (Boston, US)
Abstract Slides Video
Presentation thumbnail
A study to assess the ability of the HFA-ICOS risk stratification tool to predict cancer therapy-related cardiac dysfunction for patients receiving anthracycline chemotherapy.
Doctor A. Byrne (Godalming, GB)
Abstract Slides Video
Presentation thumbnail
Role of liraglutide on cardiotoxicity and gut microbiota changes induced by doxorubicin in rats
Doctor C. Rodrigues Tonon (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Real-world analysis of transcatheter aortic valve replacement in patients with prostate cancer and severe aortic stenosis
Doctor R. Belo Nunes (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular complications in cardio-oncology: risk assessment

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Case report on cardiotoxicity due to MEK-I and BRAF-I
thumbnail
Congress Presentation
Cardiotoxicity due to combined target therapy of malignant melanoma with full recovery after its discontinuation
thumbnail
Congress Presentation
Cardioprotective strategies and outcomes in cancer therapy-related cardiac dysfunction: insights from a single-center study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources